Freeline soars on positive early-stage data for gene therapy in Gaucher disease

Freeline Therapeutics Holdings

04/10/2023 13:02

** U.S.-listed shares of Freeline Therapeutics Holdings
 FRLN.O  jump 42.8% to $5.34 premarket
    ** Co says its experimental gene therapy FLT201 showed
positive results in an early-stage study for Gaucher disease
    ** Gaucher disease is a genetic disorder that leads to low
levels of GCase, an enzyme needed to metabolize a certain type
of fat
    ** Co says its therapy showed robust increase in GCase
levels
    ** Up to last close, shares down 47.2% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))